---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106236"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:23:27.185392+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Q2 net loss $37.3M; explores financing/strategic alternatives; cash $52M

## Summary
- Total revenue $37.9M; US XPOVIO net product revenue $29.7M (+6% YoY). Net loss $37.3M ($4.32/share).
- FY2025 total revenue guidance reaffirmed $140-155M; US XPOVIO revenue guidance updated to $110-120M.
- Cash, equivalents & investments $52M at June 30; expects liquidity to fund ops into Jan 2026 excluding $24.5M note maturity Oct 2025.
- Phase 3 SENTRY (myelofibrosis) enrollment screening close this week; top-line data expected March 2026.
- Engaged Centerview Partners to explore financing and strategic alternatives to extend cash runway and maximize value.

## SEC filing metadata
- accession: 0000950170-25-106236
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000095017025106236/0000950170-25-106236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000095017025106236/kpti-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106236
- JSON: https://secwatch.observer/filing/0000950170-25-106236.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.